$8.980
+0.485 (+5.40%)At close
Loading chart…
- High
- 9.210
- Open
- 8.360
- VWAP
- 8.85
- Volume
- 177.30K
- Mkt Cap
- —
- Low
- 8.360
- Amount
- 1.57M
- EV/EBITDA, TTM
- 0.00
Electra Therapeutics Inc is a United States-based clinical- stage biotechnology company. The Company is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Its ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and precisely depletes pathological immune cells.
AI analysis of Electra Therapeutics, Inc. Common stock (ETRA)
SellElectra Therapeutics, Inc. is not a good buy right now due to significant declines in its stock price and lack of positive financial indicators. The stock has fallen 41.93% year-to-date and 24.59% over the last 20 days, indicating a persistent downward trend. Furthermore, the company has a price-to-book ratio of -21.69, which suggests severe financial distress. Without any earnings or positive analyst ratings to support a recovery, the risks outweigh potential rewards.
Valuation Metrics
The current forward P/E ratio for Electra Therapeutics, Inc. Common stock (ETRA) is 0.00, compared to its 5-year average forward P/E of .
Events Timeline
News
8.510-23NewsfilterStar Therapeutics Secures $200 Million Financing for Growth Phase
6.010-22CNBCLatest Rating Changes on Wall Street
6.010-13CNBCLatest Wall Street Ratings Overview
6.509-21stocktwitsBiotech Sector Updates and FDA Nomination Hearing
8.509-19renaissancecapitalWeekly Overview of IPOs and SPACs Activity
ETRA FAQ — answered by Alphio AI
Electra Therapeutics Inc is a United States-based clinical- stage biotechnology company. The Company is developing therapies that target signal regulatory proteins (SIRP) for the treatment of immunological diseases and cancer. Its ELA026, is a monoclonal antibody that targets SIRP on the cell surface of myeloid and T cells and precisely depletes pathological immune cells.
Electra Therapeutics, Inc. is not a good buy right now due to significant declines in its stock price and lack of positive financial indicators. The stock has fallen 41.93% year-to-date and 24.59% over the last 20 days, indicating a persistent downward trend. Furthermore, the company has a price-to-book ratio of -21.69, which suggests severe financial distress. Without any earnings or positive analyst ratings to support a recovery, the risks outweigh potential rewards.
Community
More ↗This page is for research only and is not investment advice. Models can be wrong. Past performance does not guarantee future results.